6-KThe Wire
NOVO NORDISK A S files 6-K
Filed Mar 20, 2026 · 3mo ago · Accession 0001171843-26-001813
Plain English
Novo Nordisk announced the US FDA approval of Wegovy® HD (semaglutide 7.2 mg) for weight reduction, which demonstrated a mean weight loss of 20.7% in the STEP UP trial. The company expects to launch Wegovy® HD in the US in April 2026.
Filing details
- Company
- NOVO NORDISK A S
- Ticker
- NVO
- CIK
- 353278
- Form type
- 6-K
- Filing date
- Mar 20, 2026
- Report date
- Mar 19, 2026
- Document
- f6k_031926.htm
- Size
- 165 KB